Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 37
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
Natalie Gukasyan, Roland R. Griffiths, David B. Yaden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 707-716
Closed Access | Times Cited: 24
The need for establishing best practices and gold standards in psychedelic medicine
Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price, et al.
Journal of Affective Disorders (2023) Vol. 332, pp. 47-54
Closed Access | Times Cited: 23
Exploring mechanisms of psychedelic action using neuroimaging
David Erritzøe, Christopher Timmermann, Kate Godfrey, et al.
Nature Mental Health (2024) Vol. 2, Iss. 2, pp. 141-153
Closed Access | Times Cited: 11
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 1
Cardiovascular safety of psychedelic medicine: current status and future directions
Agnieszka Wsół
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1362-1380
Open Access | Times Cited: 20
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
Andreas Halman, Geraldine Kong, Jerome Sarris, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 16
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
Marianne Destoop, Pavel Mohr, Florence Butlen-Ducuing, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access
Neuroimaging in psychedelic drug development: past, present, and future
Matthew B. Wall, Rebecca Harding, Rayyan Zafar, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3573-3580
Open Access | Times Cited: 15
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Xuepeng Jing, Nicholas Hoeh, David B Menkes
Palliative & Supportive Care (2023) Vol. 21, Iss. 4, pp. 697-704
Open Access | Times Cited: 14
A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, et al.
Biotechnology Advances (2023) Vol. 69, pp. 108247-108247
Closed Access | Times Cited: 14
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Kevin F. Boehnke, Kasey Cox, Cody Weston, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13
Drug–drug interactions involving classic psychedelics: A systematic review
Andreas Halman, Geraldine Kong, Jerome Sarris, et al.
Journal of Psychopharmacology (2023) Vol. 38, Iss. 1, pp. 3-18
Open Access | Times Cited: 12
Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Harman Chopra, Timothy Furnish, Monica Verduzco‐Gutierrez, et al.
Clinical Case Reports (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 4
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Petros Petridis, Jack Grinband, Gabrielle Agin-Liebes, et al.
Nature Mental Health (2024) Vol. 2, Iss. 11, pp. 1408-1414
Closed Access | Times Cited: 4
Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 99-99
Open Access
The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials
Jianhua Yang, Ni Wang, Wulin Luo, et al.
Psychiatry Research (2024) Vol. 339, pp. 116043-116043
Closed Access | Times Cited: 3
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Val Bellman
Cancers (2024) Vol. 16, Iss. 9, pp. 1702-1702
Open Access | Times Cited: 2
Drug–Drug Interactions in Psychopharmacology
Jonathan E. Alpert, David Mischoulon
Elsevier eBooks (2024), pp. 621-636
Closed Access | Times Cited: 2
Drug–Drug Interactions in Psychopharmacology
Jonathan E. Alpert, David Mischoulon
Elsevier eBooks (2024), pp. 145-160
Closed Access | Times Cited: 2
Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder
Collin M. Price, Allison A. Feduccia, Katrina DeBonis
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 5, pp. 464-469
Closed Access | Times Cited: 10
MDMA-Assisted Psychotherapy for Borderline Personality Disorder
Jenna Traynor, Daniel E. Roberts, Stephen Ross, et al.
FOCUS The Journal of Lifelong Learning in Psychiatry (2022) Vol. 20, Iss. 4, pp. 358-367
Open Access | Times Cited: 10
The development of psilocybin therapy for treatment-resistant depression: an update
Anna Borissova, James Rucker
BJPsych Bulletin (2023) Vol. 48, Iss. 1, pp. 38-44
Open Access | Times Cited: 5
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
Tigran Makunts, Diane Dahill, Lisa Jerome, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 4
How Does Psilocybin Therapy Work? an Exploration of Experiential Avoidance as a Putative Mechanism of Change
Richard J. Zeifman
(2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top